住居での交通への曝露は,冠動脈動脈硬化症と関連しています
B Hoffmann1, S Moebus, S Möhlenkamp
1Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. barbara.hoffmann@uk-essen.de
Circulation
|July 20, 2007
まとめ
主要な道路の近くに住んでいると,冠動脈の化がより多く起こる. 空気汚染の一種である長期的な交通曝露は,動脈硬化症の発症を加速する可能性があります.
科学分野:
- 環境衛生 環境衛生 環境衛生
- 心血管伝染病学 心血管伝染病学
- 公衆衛生は公衆衛生である.
背景:
- 細粒子物質 (PM2.5) の空気の汚染に長期にわたる曝露は,動脈硬化症の潜在的な加速因子である.
- 交通源に近い住宅地が,大気汚染物質の主要被曝経路である.
研究 の 目的:
- 交通や微細粒子物質 (PM2.5) に長期にわたる住宅被曝と冠動脈動脈硬化症の程度との関連性を調査する.
- 交通の接近と冠動脈結石化 (CAC) の関係を定量化するために.
主な方法:
- ドイツのハインツ・ニックスドルフリコール研究 (Heinz Nixdorf Recall Study) の4494人の参加者 (45歳から74歳) のベースラインデータを利用した.
- 住宅から主要道路までの距離を計算し,分散モデルを使用して年間PM2.5濃度を割り当てました.
- 電子ビームコンピュータトモグラフィーによる冠動脈カルシフィケーション (CAC) を評価し,リスク因子をコントロールしながら,ロジスティックおよび線形回帰を用いて関連性を分析した.
主要な成果:
- 主要道路 (<50m, 51-100m, 101-200m) に近い地域に住む参加者は,200m以上離れた地域に住む参加者と比較して,CACが高い確率が著しく高かった.
- 主要道路までの距離を半分に減らすことは,CACの7.0%の増加と関連していました.
- 微細粒子物質の曝露は,少なくとも5年間フルタイムで働いていない個体においてのみ,CACと関連付けられました.
結論:
- 高い交通密度の長期的住宅暴露は,冠動脈動脈硬化症の程度と有意に関連しています.
- 主要な道路への近接は,冠動脈疾患の発生と進行における重要な要因です.
関連する概念動画
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741